CR Bard (NYSE:BCR)

CR Bard is a world leader in the manufacturing and marketing of innovative products, improving medical technologies in the fields of vascular, of the urology, oncology and surgery. BARD markets its products and services worldwide to hospitals, healthcare professionals and long-term care facilities. BARD's core values are quality, integrity, service and innovation. 

Oncology was one of BARD's fastest growing therapeutic areas, with over $191.3T of sales growth. cancer is in fact the second leading cause of death in developed countries and the third in the world. Billions of dollars are spent each year on cancer research and treatment. In developed countries, Cancer is responsible for approximately 25% of all deaths, after cardiovascular diseases. The most common methods of cancer treatment are surgery, radiation therapy, and chemotherapy, which are often used together to treat various aspects of the disease. Bard has a wide range of products that are used to treat and manage various aspects of cancer. 

The company's shares fell by more than 11% on July 22.. Bard actually reported a loss of $1.45 per share, despite sales increasing by more than $71.35 per share. Based on these figures, Bard shares are currently trading at more than 25 times earnings, which is a lot for a company that is expected to grow by $111.35 per share annually over the next five years alone.

Yet society had accustomed us to a solid and constant progression of its profits for several years. The dividend has also been increased for 39 consecutive years, but to a lesser extent, with an average annual growth of 6,64%. This conservative policy is also reflected in the distribution ratio minimal (19.27%), despite the drop in profit, and in the dividend yield very low (0.78%).

Bard's performance is very little linked to that of the market. The Beta is only 0.33, with a volatility in CHF of 8.24%, which is less than half of the SMI. BCR's performance compared to the S&P 500 has been particularly marked since 2000.

BCR has the advantage of reacting positively to a fall in the dollar, thanks to its good international exposure.

Our analysis model considers BCR as a stock to hold if you already have it in your portfolio. Of course the price has fallen, but so have the profits, so there is no reason to panic in either direction. We must not forget that Bard is a solid company: the The current ratio also stands at 5.7, while the debt-to-equity ratio stands at 0.48.